Babies are Africa's malaria warriors

By Andrew Quinn

KILIFI, Kenya (Reuters) - For a footsoldier on the cutting-edge of a global public health experiment, Michael Kenyali was looking a little wobbly.

The bright eyed two-year-old, stumbling towards his mother and wailing to be fed, is part of an army of babies enlisted to test a new vaccine researchers hope will help drive back malaria, one of Africa's biggest killers.

"My firstborn used to have problems with malaria. He would go into seizures," said Michael's mother Mariam, sitting outside her small, neat homestead near the Kenyan coastal town of Kilifi as her other children, aged 11, 6, and 4, looked on.

"The baby was the same before he went into the study," she said, smoothing Michael's forehead. "But since he got into the vaccine study, he hasn't had any problems."

It's still to early to tell if Michael's good health has anything to do with the "RTS,S" malaria vaccine, which will be rolled out early next year in the largest clinical trial ever undertaken in Africa.

Michael, who participated in one of the preliminary studies, received either the malaria vaccine or a similar dose of rabies vaccine, a "placebo" designed to benefit participants even if they were not in the malaria group.

Researchers hope results from the coming trial, involving 16,000 children in seven African countries and funded by groups supported by the Gates Foundation among others, will mirror data from a 2004 study in Mozambique.

That study of more than 2,000 children showed the vaccine reduced all cases of clinical malaria by 35 percent and the worst cases of the disease by almost 50 percent.